Developer docs
API playgroundTry for free, no card

Search company profiles

Sequent Medical

Full company profile

uuid0007lau

Namestring
Sequent Medical
Websiteurl
sequentmedical.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Sequent Medical is a private medical device company founded in 2007 and headquartered in Aliso Viejo, California. The company develops catheter-based neurovascular technologies, with its core product being the Woven EndoBridge (WEB) intrasaccular device — a minimally invasive implant designed to treat unruptured wide-necked bifurcation aneurysms from inside the aneurysm sac, blocking blood flow and promoting healing as an alternative to conventional coiling or surgical clipping.

The company targets neurosurgery and neurointerventional radiology departments within hospitals and medical centers, addressing anatomically challenging lesions that are difficult to treat with standard endovascular or surgical approaches. Clinical data cited for the WEB device includes a 98% procedural success rate, 82% adequate occlusion at one-year follow-up, and a 3.9% major adverse event rate, with potential reductions in reliance on dual antiplatelet therapy and thromboembolic risk compared to conventional treatments.

Sequent Medical has raised approximately $65M across multiple funding rounds between 2009 and 2014, with a consistent investor syndicate comprising Delphi Ventures, Domain Associates, U.S. Venture Partners, and Versant Ventures. The company operates with 51-100 employees and is led by specialized clinical/regulatory and quality assurance executives. Its revenue model is tied to direct sales of the WEB device into specialized hospital neurovascular programs, though pricing is not publicly disclosed.

Short descriptiontext

Sequent Medical is a private medical device company that develops the Woven EndoBridge (WEB), a catheter-based intrasaccular implant for treating unruptured wide-necked bifurcation aneurysms, serving hospital neurosurgery and neurointerventional radiology departments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAliso Viejo, United States
HQ citystring
Aliso Viejo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
neurovascular medical devices, intracranial aneurysm treatment, intrasaccular embolization device, endovascular neurosurgery devices, catheter-based neurointervention
Industry1 code
1Thrombectomy, Embolic Protection & Stroke Intervention Devices
CodeHLAHAFAJPrimaryYes
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurovascular Medical Devices
Social media profiles1 record
Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sequent Medical develops and sells catheter-based neurovascular devices, with its core product being the Woven EndoBridge (WEB) intrasaccular device for the endovascular treatment of unruptured wide-necked bifurcation aneurysms. The WEB is delivered via catheter into the aneurysm sac to block blood flow and promote healing, offering a minimally invasive alternative to surgical clipping and conventional coiling approaches.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sequent Medical offers the Woven EndoBridge (WEB) intrasaccular device as its core product for neurovascular applications. The WEB device is designed for treating wide-necked bifurcation aneurysms and represents a minimally invasive therapeutic alternative to conventional surgical or endovascular approaches.

Product and service1 record
1Woven EndoBridge (WEB)
CategoryNeurovascular Medical Devices
Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1MicroVention (Terumo)
TypeDirect peer
Description

A leader in catheter-based neurovascular devices including coils, flow diverters, and intrasaccular products. Direct overlap with WEB in the endovascular aneurysm treatment market, addressing the same neurointerventional customer base.

2Stryker Neurovascular
TypeBroad incumbent
Description

Major neurovascular franchise offering coils, stents, and flow diversion products. Competes with Sequent across the aneurysm treatment continuum and shares the same neurointerventional hospital customer base.

3Medtronic Neurovascular
TypeBroad incumbent
Description

A large incumbent in neurovascular devices including coils, flow diverters, and access technologies. Competes with Sequent for hospital contracts and shares the same neurointerventional radiology and neurosurgery customers.

4Penumbra
TypeDirect peer
Description

Focused on neurovascular and peripheral vascular devices, with a growing portfolio in the aneurysm and stroke treatment space. Emerging direct competitor in neurovascular catheter-based therapies.

5Cerenovus (Johnson & Johnson MedTech)
TypeBroad incumbent
Description

J&J's neurovascular business offering coils, flow diverters, and access products. A broad incumbent competing with Sequent for endovascular aneurysm treatment volumes.

6Rapid Medical
TypeEmerging player
Description

Emerging neurovascular company developing devices for aneurysm and stroke treatment. Comparable in stage and in the same catheter-based neurovascular category that overlaps with WEB.

7Phenox
TypeEmerging player
Description

European neurovascular device company producing coil and flow-related products for aneurysm treatment. Comparable niche neurovascular focus and endovascular catheter-based approach.

8Balt USA
TypeEmerging player
Description

Specializes in neurovascular and interventional neuroradiology devices, including coils and flow-related products. Shares the same aneurysm treatment customer base as Sequent.

9MIVI Neuroscience
TypeEmerging player
Description

Emerging neurovascular company developing access and treatment devices for ischemic and hemorrhagic stroke. Operates in the same neurointerventional hospital channel as Sequent.

10Kaneka Neurovascular
TypeRegional player
Description

Neurovascular device company with a portfolio of coils and adjunctive technologies. Comparable in product category but with a focus that is more regional, complementing the global competitor set.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sequent Medical

Neurovascular Medical Devicessequentmedical.com

Sequent Medical is a private medical device company that develops the Woven EndoBridge (WEB), a catheter-based intrasaccular implant for treating unruptured wide-necked bifurcation aneurysms, serving hospital neurosurgery and neurointerventional radiology departments.

What Sequent Medical does

Sequent Medical is a private medical device company founded in 2007 and headquartered in Aliso Viejo, California. The company develops catheter-based neurovascular technologies, with its core product being the Woven EndoBridge (WEB) intrasaccular device — a minimally invasive implant designed to treat unruptured wide-necked bifurcation aneurysms from inside the aneurysm sac, blocking blood flow and promoting healing as an alternative to conventional coiling or surgical clipping.

The company targets neurosurgery and neurointerventional radiology departments within hospitals and medical centers, addressing anatomically challenging lesions that are difficult to treat with standard endovascular or surgical approaches. Clinical data cited for the WEB device includes a 98% procedural success rate, 82% adequate occlusion at one-year follow-up, and a 3.9% major adverse event rate, with potential reductions in reliance on dual antiplatelet therapy and thromboembolic risk compared to conventional treatments.

Sequent Medical has raised approximately $65M across multiple funding rounds between 2009 and 2014, with a consistent investor syndicate comprising Delphi Ventures, Domain Associates, U.S. Venture Partners, and Versant Ventures. The company operates with 51-100 employees and is led by specialized clinical/regulatory and quality assurance executives. Its revenue model is tied to direct sales of the WEB device into specialized hospital neurovascular programs, though pricing is not publicly disclosed.

Sequent Medical firmographics

Firmographics
Name
Sequent Medical
Website
https://sequentmedical.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Sequent Medical is a private medical device company that develops the Woven EndoBridge (WEB), a catheter-based intrasaccular implant for treating unruptured wide-necked bifurcation aneurysms, serving hospital neurosurgery and neurointerventional radiology departments.
Ownership category
akta.pro rank

Sequent Medical industry classification

Industry
Product category
Neurovascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

  • Neurovascular medical devices
  • Intracranial aneurysm treatment
  • Intrasaccular embolization device
  • Endovascular neurosurgery devices
  • Catheter-based neurointervention

Where Sequent Medical is headquartered

Location

Headquarters

HQ city
Aliso Viejo
HQ country
United States
HQ region
North America

Markets served

Sequent Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Sequent Medical product offering

Product offering

Core offering

Sequent Medical develops and sells catheter-based neurovascular devices, with its core product being the Woven EndoBridge (WEB) intrasaccular device for the endovascular treatment of unruptured wide-necked bifurcation aneurysms. The WEB is delivered via catheter into the aneurysm sac to block blood flow and promote healing, offering a minimally invasive alternative to surgical clipping and conventional coiling approaches.

Product overview

Sequent Medical offers the Woven EndoBridge (WEB) intrasaccular device as its core product for neurovascular applications. The WEB device is designed for treating wide-necked bifurcation aneurysms and represents a minimally invasive therapeutic alternative to conventional surgical or endovascular approaches.

Differentiator

Problem solved

Functional benefit

Products and services

  • Woven EndoBridge (WEB)

Companies that use Sequent Medical

Customer profile

Segments1 record

Ideal customer profiles1 record

Sequent Medical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Sequent Medical partnerships and signals

Strategic signal

Expansion highlights3 records

Sequent Medical competitors and assessment

Company assessment

Direct peers

  • MicroVention (Terumo): A leader in catheter-based neurovascular devices including coils, flow diverters, and intrasaccular products. Direct overlap with WEB in the endovascular aneurysm treatment market, addressing the same neurointerventional customer base.
  • Penumbra: Focused on neurovascular and peripheral vascular devices, with a growing portfolio in the aneurysm and stroke treatment space. Emerging direct competitor in neurovascular catheter-based therapies.

Broad incumbents

  • Stryker Neurovascular: Major neurovascular franchise offering coils, stents, and flow diversion products. Competes with Sequent across the aneurysm treatment continuum and shares the same neurointerventional hospital customer base.
  • Medtronic Neurovascular: A large incumbent in neurovascular devices including coils, flow diverters, and access technologies. Competes with Sequent for hospital contracts and shares the same neurointerventional radiology and neurosurgery customers.
  • Cerenovus (Johnson & Johnson MedTech): J&J's neurovascular business offering coils, flow diverters, and access products. A broad incumbent competing with Sequent for endovascular aneurysm treatment volumes.

Emerging players

  • Rapid Medical: Emerging neurovascular company developing devices for aneurysm and stroke treatment. Comparable in stage and in the same catheter-based neurovascular category that overlaps with WEB.
  • Phenox: European neurovascular device company producing coil and flow-related products for aneurysm treatment. Comparable niche neurovascular focus and endovascular catheter-based approach.
  • Balt USA: Specializes in neurovascular and interventional neuroradiology devices, including coils and flow-related products. Shares the same aneurysm treatment customer base as Sequent.
  • MIVI Neuroscience: Emerging neurovascular company developing access and treatment devices for ischemic and hemorrhagic stroke. Operates in the same neurointerventional hospital channel as Sequent.

Regional players

  • Kaneka Neurovascular: Neurovascular device company with a portfolio of coils and adjunctive technologies. Comparable in product category but with a focus that is more regional, complementing the global competitor set.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Sequent Medical social profiles

Digital presence

Sequent Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sequent Medical leadership team

Management profile

Number of profiles

Profiles2 records

Sequent Medical funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sequent Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sequent Medical

What does Sequent Medical do?

Sequent Medical develops and sells catheter-based neurovascular devices, with its core product being the Woven EndoBridge (WEB) intrasaccular device for the endovascular treatment of unruptured wide-necked bifurcation aneurysms. The WEB is delivered via catheter into the aneurysm sac to block blood flow and promote healing, offering a minimally invasive alternative to surgical clipping and conventional coiling approaches.

When was Sequent Medical founded?

Sequent Medical was founded in 2007. It employs 11 to 50 people.

Where is Sequent Medical based?

Sequent Medical is headquartered in Aliso Viejo, United States, in the North America region.

Who are Sequent Medical's main competitors?

Direct peers on record are MicroVention (Terumo) and Penumbra. Broad incumbents are Stryker Neurovascular, Medtronic Neurovascular and Cerenovus (Johnson & Johnson MedTech). Emerging players are Rapid Medical, Phenox, Balt USA and MIVI Neuroscience. Kaneka Neurovascular is listed as a regional player.

Does Sequent Medical have an API?

No public API is recorded for Sequent Medical.

What industry is Sequent Medical in?

Sequent Medical's product category is Neurovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNovel Intrasaccular Aneurysm Treatment Device Receives FDA PMA ApprovalMicroVention, Inc., a U.S.-based subsidiary of Terumo Corporation, announced on January 7, 2019 that the FDA granted Premarket Approval (PMA) for the WEB Aneurysm Embolization System, making it the first and only approved device in the new category of intrasaccular flow disruptors for treating intracranial wide neck bifurcation aneurysms. The pivotal WEB-IT trial demonstrated an 84.6% adequate occlusion rate and an exceptional safety profile, with the device already having been used safely in over 6,000 cases globally following its CE mark in 2010. The WEB System was originally developed by Sequent Medical, Inc., which Terumo acquired in 2016, integrating the technology into MicroVention's neurovascular portfolio.PR NewswireTerumo Corporation Acquires Sequent MedicalTerumo Corporation, through its subsidiary MicroVention, Inc., has agreed to acquire Sequent Medical, Inc. for $280 million at closing with up to an additional $100 million tied to development and commercial milestones, with completion expected in July or August 2016 pending regulatory approvals. Sequent Medical, headquartered in Aliso Viejo, California with European operations in Bonn, Germany, developed the WEB Aneurysm Embolization System, the world leader in intrasaccular flow disruptors for aneurysm treatment, which has received CE Mark approval and been used in over 3,000 patients worldwide. MicroVention intends to pursue FDA approval to bring the WEB System to the U.S. market, where it will complement its existing portfolio of neurovascular products.PR NewswireSequent Medical Announces Completion of Patient Enrollment in IDE Study for the WEB Aneurysm Embolization SystemSequent Medical, Inc. announced completion of patient enrollment in its WEB-IT pivotal trial evaluating the WEB Aneurysm Embolization System, enrolling 150 patients at 31 sites across the U.S., Canada, and Europe. The WEB-IT study is the first-ever pivotal study of an intrasaccular flow disruptor designed to treat wide-necked intracranial bifurcation aneurysms. The company expects to use the data to support its objective of obtaining U.S. regulatory approval for the device.PR NewswireSequent Medical annonce lancement de l'étude pour le système WEB d'embolisation des anévrismes dans les anévrismes rompusSequent Medical announced the commencement of patient recruitment for the CLARYS study, a clinical trial evaluating the safety and efficacy of its WEB embolization system specifically for ruptured intracranial aneurysms. The multicenter study will enroll 50 patients across 15 sites in France and Germany to assess rebleeding rates at 30 days. This initiative represents a critical step in building clinical evidence for the device's application in treating ruptured aneurysms.PR NewswireSequent Medical anuncia el comienzo del estudio para el sistema de embolización de aneurisma WEB en aneurismas quebradosSequent Medical, Inc. announced the initiation of patient recruitment for the CLARYS clinical study to evaluate the safety and efficacy of the WEB aneurysm embolization system for treating ruptured intracranial aneurysms. The prospective multicenter trial will enroll 50 patients at up to 15 sites in France and Germany, making it the first study focused exclusively on the WEB system for this patient population. Professor Laurent Spelle from Bicetre University Hospital in Paris recruited the first patient, with the primary objective being the aneurysm re-hemorrhage rate at 30 days.PR NewswireSequent Medical gibt Start einer Studie für das WEB-System zur Embolisation von Aneurysmen bei rupturierten Aneurysmen bekanntSequent Medical, Inc. announced the enrollment of the first patient in the CLARYS clinical study to evaluate the safety and efficacy of the WEB aneurysm embolization system for treating ruptured intracranial aneurysms. The prospective multicenter study will enroll 50 patients at up to 15 trial centers in France and Germany, with the primary endpoint being the rate of aneurysm re-bleeding after 30 days. Prof. Laurent Spelle of the Universitätsklinik Bicêtre in Paris enrolled the first patient and serves as the study's principal investigator.FinSMEsSequent Medical Closes $20M Series D VC FinancingSequent Medical closed a $20M Series D financing led by Delphi Ventures. The funds will support a planned US IDE clinical study for its WEB Aneurysm Embolization System and broaden its product portfolio. The company, founded in 2007, has CE-marked devices but the WEB system is not approved in the US.VC News DailySequent Medical Closes $20M in Series DSequent Medical, Inc. announced the closing of a $20.0 million Series D venture capital financing, led by Delphi Ventures with participation from Domain Associates, US Venture Partners, and Versant Ventures. The funds will support continued introduction of the WEB Aneurysm Embolization System and execution of the planned US IDE clinical study. The company is a privately held medical-device firm dedicated to catheter-based neurovascular technologies, headquartered in Aliso Viejo, California with European operations in Bonn, Germany.VC News DailySequent Medical Closes $26MSequent Medical has closed a $26.0 million Series C venture capital financing round led by Delphi Ventures, with participation from existing investors Versant Ventures, US Venture Partners, and Domain Associates. James Bochnowski of Delphi Ventures will join Sequent Medical's Board of Directors as part of the transaction. The company will use the funds to support clinical, commercial, and technology development programs for its WEB Aneurysm Embolization System product line.